ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: fracture

FDA Greenlights Osteoporosis Drug for Postmenopausal Women

Saumya Joseph  |  April 11, 2019

(Reuters)—The U.S. Food and Drug Administration says it has approved Amgen’s osteoporosis treatment for postmenopausal women who are at high risk of fracture. Evenity (romosozumab-aqqg), developed jointly with Belgium-based UCB SA, helps reduce the risk of fracture by increasing bone mass and mildly inhibiting the break down of bone minerals. Romosozumab-aqqg belongs to a new…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:AmgenFDAFDA approvalFracturesOsteoporosisosteoporosis treatmentspostmenopausalpostmenopausal womenromosozumabromosozumab-aqqgU.S. Food and Drug Administration (FDA)

Tracking Bone Deterioration in Patients with Ankylosing Spondylitis

Lara C. Pullen, PhD  |  April 2, 2019

Trabecular bone score and high-resolution peripheral quantitative computed tomography may be effective for evaluating bone impairment in patients ankylosing spondylitis (AS). Rheumatologists may be able to use these methods, complementary to dual-energy X-ray absorptiometry, to identify bone quality deterioration in AS patients.

Filed under:Axial SpondyloarthritisConditionsOsteoarthritis and Bone Disorders Tagged with:Ankylosing Spondylitisbone densitybone mineral density (BMD)Osteoporosisspine

Women Diagnosed Years Later than Men for Same Diseases

Tamara Mathias  |  March 27, 2019

(Reuters Health)—For a wide range of diseases, diagnosis comes later in life for women than for men, according to a large Danish study. Researchers don’t know whether the later diagnoses are due to genetics, the environment, possible biases in the healthcare system—or some combination of reasons. The study of health data from 6.9 million Danish…

Filed under:Conditions Tagged with:DiagnosisWomen

Osteoporosis Experts Discuss Bisphosphonates, Chronic Kidney Disease

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—The osteoporosis session at the 2018 ACR/ARHP Annual Meeting opened with a discussion by Kenneth Saag, MD, MSc, professor of medicine at the University of Alabama, Birmingham, in which he highlighted adverse events associated with osteoporosis medications. Dr. Saag began his presentation by emphasizing that, above all, the audience should keep in mind that the…

Filed under:ConditionsMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:2018 ACR/ARHP Annual MeetingAssociation of Rheumatology Professionals (ARP)bisphosphonateschronic kidney diseaseOsteoporosis

Insights on the Diagnosis & Treatment of Low Back & Hip Pain

Susan Bernstein  |  March 19, 2019

CHICAGO—Two experts presented insights on the diagnosis and treatment of low back and hip pain, including a refresher course on the mechanical structures involved, in Anatomy in a Day: Demystifying Low Back Pain and Lateral Hip Pain: New Patho-Anatomical Perspectives, a session at the 2018 ACR/ARHP Annual Meeting. Low Back Pain Avoid using such terms…

Filed under:ConditionsMeeting Reports Tagged with:2018 ACR/ARHP Annual Meetinghip painlow back painUltrasound

Disease Mimicry: Genetic Diseases Can Produce Rheumatic Symptoms

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—The 2018 ACR/ARHP Annual Meeting session on genetic mimics of rheumatic disease began with a description of a patient who presented with the symptoms of childhood-onset lupus but instead had a well-defined genetic disease: lysinuric protein intolerance (LPI). Lindsay Burrage, MD, PhD, assistant professor of molecular and human genetics at Baylor College of Medicine, Houston,…

Filed under:ConditionsMeeting Reports Tagged with:2018 ACR/ARHP Annual MeetingFabry diseasegenetic diseaselysinuric protein intolerancemimics

State-of-the-Art Approaches to Rheumatic Disease Diagnosis, Management & Treatment

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—Held during the 2018 ACR/ARHP Annual Meeting, the ACR Review Course covered a wide range of topics for rheumatologists—from advances in pain and rheumatic disease management to the intersection of rheumatology and neurology. Session speakers shared insights, as well as state-of-the-art approaches to diagnosis, management and treatment. Inflammatory Myopathies Julie J. Paik, MD, MHS, assistant…

Filed under:ConditionsMeeting ReportsOsteoarthritis and Bone DisordersPain SyndromesSystemic Lupus Erythematosus Tagged with:2018 ACR/ARHP Annual MeetingFibromyalgiaOsteoporosisperioperative period

Tanezumab for OA Pain

Michele B. Kaufman, PharmD, BCGP  |  February 21, 2019

In a recent study, tanezumab proved more effective than placebo in treating patients with moderate to severe pain caused by hip or knee osteoarthritis…

Filed under:AnalgesicsDrug Updates

WindNight / shutterstock.com

Why & How Our Biologic Drug Discussion with Patients Should Evolve

Paul H. Caldron, DO, PhD, MBA, & John R.P. Tesser, MD  |  February 17, 2019

As we turn the corner on the second decade of biologic use for rheumatic disorders, a reappraisal of approach in our communication with patients is due. In practice, the impact these agents have on patients’ lives justifies the friction rheumatologists face when connecting patients to them. You can understand why older rheumatologists who apprenticed on…

Filed under:Biologics/DMARDsResearch RheumRheumatoid ArthritisSpeak Out Rheum Tagged with:OpinionSpeak Out Rheumatology

FDA Advisory Committee Votes in Favor of Romosozumab Approval

Michele B. Kaufman, PharmD, BCGP  |  January 30, 2019

An FDA advisory committee voted 18-1 in favor of approving romosozumab to treat postmenopausal women with osteoporosis.

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:boneFDAOsteoporosisromosozumabU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 44
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences